Miscellaneous ocular agents:
Indications for: LUCENTIS
Neovascular (wet) age-related macular degeneration (AMD). Macular edema following retinal vein occlusion (RVO). Diabetic macular edema (DME). Diabetic retinopathy (DR). Myopic choroidal neovascularization (mCNV).
Adult Dosage:
Give by intravitreal inj. AMD: 0.5mg once a month (approx. 28 days); or 3 monthly doses followed by less frequent dosing (less effective); or 0.5mg every 3 months after 4 monthly doses (less effective). Monitor regularly. RVO: 0.5mg once a month (approx. 28 days). DME, DR: 0.3mg once a month (approx. 28 days). mCNV: 0.5mg once a month (approx. 28 days) for up to 3 months; may retreat if needed.
Children Dosage:
Not established.
LUCENTIS Contraindications:
Ocular or periocular infections.
LUCENTIS Warnings/Precautions:
Monitor intraocular pressure prior to and 30mins after inj. Monitor for perfusion of optic nerve and for infection following the inj (endophthalmitis and retinal detachments possible). Pregnancy; may cause embryo-fetal toxicity. Nursing mothers.
LUCENTIS Classification:
Vascular endothelial growth factor (VEGF) inhibitor.
Adverse Reactions:
Conjunctival hemorrhage, eye pain, vitreous floaters, increased intraocular pressure, intraocular inflammation; rare: arterial thromboembolic events, fatal events (with DME, DR).
Generic Drug Availability:
NO
How Supplied:
Single-use prefilled syringe, single-use vial—1
